Quest Diagnostics Acquires Cleveland HeartLab, Formalizes R&D Collaboration

We represented Quest Diagnostics (NYSE: DGX) in its acquisition of Cleveland HeartLab. The acquisition combines the expertise of Cleveland HeartLab’s personalized evaluation of heart disease risk based on inflammation and other markers with Quest’s Cardio IQ® lipid particle analysis and genetic and metabolic testing leadership. In connection with the acquisition, Quest Diagnostics and Cleveland Clinic have also finalized a strategic collaboration intended to speed the commercialization of emerging innovations at Cleveland Clinic, including its Lerner Research Institute. Terms of the transaction were not publicly disclosed.

Quest Diagnostics is the world’s leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions.

You Also May Be Interested In:

  • Representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge with Strategic Storage Trust II, Inc., (SST II) in an all-cash merger valued at $340 million expected to close during the first quarter of 2019, subject to customary closing conditions, including the approval of SSGT’s stockholders

    We are representing the independent Special Committee of Strategic Storage Growth Trust, Inc. (SSGT), in its definitive agreement to merge...
    Client Type: Private Company
  • Represented Wright Medical Group in its acquisition of Cartiva, Inc.

    We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held...
    Client Type: Public Company
  • We represented NN, Inc. (Nasdaq: NNBR) in its public offering of 14,375,000 shares of common stock, which was composed of...
    Client Type: Public Company